Phase 1 N=33 Therapeutic Vaccine for HIV
HIV · Therapeutic Vaccine
Primary: The Rate of Related Adverse Events in Subjects Who Began cART During Acute or Early HIV-1 Infection. — 0; 0 Related Adverse Events
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=16,395 HIV Vaccine Trial in Thai Adults
HIV Infection
Primary: Kaplan-Meier Estimate of HIV-1 Infection Rate in Intent to Treat Population — 0.15; 0.38; 0.41; 0.64 Percetage of subjects
Phase 2 N=92 Immunogenicity and Safety of 4 Prime-boost Combinations of HIV Vaccine Candidates in Healthy Volunteers
HIV Infection
Primary: Evaluation of the Safety of MVA HIV-B at Week 2 in Arm 1 — 22 Participants
Phase 1 N=14 The Safety and Immunogenicity of a Potential HIV Vaccine
HIV Infections
Primary: Number of Participants With Moderate or Greater Reactogenicity (i.e., Solicited Adverse Events) — 2; 4 Participants
Phase 1 N=16 Dose, Safety, Tolerability, and Immunogenicity of an HIV-1 Vaccine, VRC-HIVRGP096-00-VP, With Alum in Healthy Adults
Human Immunodeficiency Virus Prevention · Human Immunodeficiency Virus (HIV)
Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms For 7 Days After Each Product Administration — 1; 1; 0; 0 Participants
Phase 2 N=56 Therapeutic Vaccination in Treated HIV Disease
HIV-1-infection
Primary: The Percentage of Participants With Grade 3 or Higher Treatment-related Adverse Events — 0; 0; 0; 0 Participants
Phase 2 N=11 Autologous Dendritic Cell Vaccine in HIV1 Infection
HIV Infections
Primary: Safety and Tolerability of Autologous HIV-1 ApB DC Vaccine. — 2 participants with Grade 3 events related
Phase 2 N=109 Human Papillomavirus Vaccine Therapy in Treating Men With HIV-1 Infection
Infection · Precancerous Condition
Primary: Occurrence of ≥ Grade 3 Adverse Events Probably or Definitely Related to the Vaccine — 0 participants
Phase 2 N=149 Vaccine Therapy in Preventing Human Papillomavirus Infection in Young HIV-Positive Male Patients Who Have Sex With Males
Anal Cancer · Nonneoplastic Condition · Penile Cancer
Primary: Incidence of AIN or Anal/Perianal Condyloma Associated With HPV 6 DNA — 0.0; 11.1 Events per 100 person years — p=0.112
Phase 1 N=23 HIV-1 Peptide Immunisation of Individuals in West Africa to Prevent Disease
Aids, Cdc Group I
Primary: Tolerability and Safety of the Treatment. — 0; 0 participants
Phase 3 N=5,404 Pivotal Phase 2b/3 ALVAC/Bivalent gp120/MF59 HIV Vaccine Prevention Safety and Efficacy Study in South Africa
HIV Infections
Primary: Incidence Rate of HIV-1 Infection Diagnosed After Enrollment (Concurrent With First Vaccination) Through 24 Months After Enrollment — 0.034; 0.033; 0.034; 0.033 events…
Phase 1 N=150 Vaccine Therapy in Preventing HPV in HIV-Positive Women in India
Cervical Cancer · Nonneoplastic Condition · Precancerous Condition
Primary: Safety, in Terms of Grade 3 or 4 Adverse Events Attributed to the Vaccine, According to NCI CTCAE v3.0 — 6.0 Grade 3/4 adverse events per 100 patient
Phase 2 N=252 A Safety and Immune Response Study of 2 Experimental HIV Vaccines
HIV Infection
Primary: Part A: Number of Participants Reporting Local Reactogenicity Signs and Symptoms During the Primary Vaccine Regimen — 42; 26; 126; 16 Participants
Phase 2 N=15 A Pilot Study of a Dendritic Cell Vaccine in HIV-1 Infected Subjects
HIV-1 Infection · HIV Infections
Primary: Safety of the DC Vaccine (as Measured by Frequency of Adverse Events) — 0; 0 participants
Phase 1 N=68 Clinical Trial of HIV Vaccine Combinations in Healthy Men and Women
Human Immunodeficiency Virus
Primary: Number of Participants With Mucosal Binding IgG Antibodies to HIV CN54gp140 Antigen — 0; 3; 1; 6 Participants
Phase 2 N=132 Safety and Immunogenicity of Clade C ALVAC and gp120 HIV Vaccine
HIV Infections
Primary: Occurrence of Vaccine-induced Systemic IgG Ab Binding to the 3 gp120 Env Proteins Contained in the Vaccine Regimen (ZM96, TV1.C, and 1086.C) in Group 1 and Group 2 — 29…
Phase 1 N=143 A Study to Assess the Safety and Immune Response to Env-C DNA and Protein Vaccines in Kenya
HIV Infections
Primary: Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) — 23; 27; 25; 10 Participants
Phase 2 N=136 Immunogenicity Study of Vacc-4x Versus Placebo in Patients Infected With HIV
HIV I Infection
Primary: Proportion of Subjects Who Require Resumption of ART Between the Interruption of ART at Week 28 and End of Study at Week 52. — 88; 40; 88; 38 participants
Phase 2 N=180 Dose-ranging Study to Evaluate the Safety & Immunogenicity of a HIV Vaccine 732461 in Healthy HIV Seronegative Volunteers
AIDS · HIV Infections
Primary: Number of Subjects With Any and Grade 3 Solicited Local Symptoms — 2; 0; 2; 49 Participants
Phase 2 N=190 Efficacy and Safety of GSK Biologicals HIV Vaccine in Antiretroviral Therapy (ART)-naïve HIV-1 Infected Persons
AIDS
Primary: Geometric Mean Change in Human Immunodeficiency Virus Type 1 (HIV-1) Viral Load (VL) From Baseline — 1.0; 1.5; 1.3 RNA copies/mL
Phase 2 N=581 Safety and Immunogenicity of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in HIV Infected Patients
HIV Infections
Primary: Serious Adverse Events — 0; 17; 0; 6 Participants
Phase 1 N=17 MRKAd5 HIV-1 Gag Vaccine (V520) in Subjects With Chronic Hepatitis C (V520-022) (COMPLETED)
Hepatitis C
Primary: Number of Participants With Vaccine-related Clinical (Systemic and Injection-site), and Laboratory Adverse Events (AE) — 5; 1; 3; 1 Participants
Phase 2 N=319 Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women
HIV Infections · Sexually Transmitted Diseases
Primary: Percentage of Participants With HPV6 Antibody Development From Seronegative Status at Baseline to Seropositive Status a Month After Completion of HPV Vaccination Series…
Phase 1 N=9 Single DermaVir Immunization in HIV-1 Infected Patients on HAART
HIV Infection
Primary: Grade 3 Adverse Event Related to DermaVir Treatment — 0; 0; 0 participants
Phase 4 N=182 Immunogenicity of Hepatitis B Vaccination in HIV-infected Adults
Hepatitis B Vaccine
Primary: Number and Percentage of Participants With Anti-HBs Seroconversion at Month 7 — 75; 69 Participants
Phase 4 N=371 Comparison of Three Hepatitis B Vaccination Regimens in HIV-Positive Youth
HIV Infection · Hepatitis B
Primary: Sero-response to Hepatitis B Surface Antigen — 60; 73.2; 75.4 percentage of participants who resonded — p=0.0440
Phase 4 N=195 Improving Immunogenicity of Influenza Vaccine in HIV Infected Individuals
HIV Infection
Primary: Immunogenicity — 22; 25; 344; 686 Geometric Mean antibody titer
Phase 2 N=334 Evaluating the Safety and Immunogenicity of HIV Clade C DNA Vaccine and MF59- or AS01B-Adjuvanted Clade C Env Protein Vaccines in Various Combinations in Healthy, HIV-Uninfected Adults
HIV Infections
Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness — 5; 7; 6; 8 Participants
Phase 2 N=192 H1N1 Vaccine at Two Dose Levels in HIV Positive Adults
Influenza
Primary: Number of Participants in the CD4 Less Than 200/mL Stratum With 4-Fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Influenza…
Phase 1 N=60 Evaluating the Safety and Immunogenicity of Env (A,B,C,A/E)/Gag (C) DNA and gp120 (A,B,C,A/E) Protein/GLA-SE HIV Vaccines, Given Individually or Co-administered, in Healthy, HIV-1-Uninfected Adults
HIV Infections
Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms — 2; 5; 5; 3 Participants